首页> 外文OA文献 >Transcription Enhancer Factor 3 (TEF3) Mediates the Expression of Down Syndrome Candidate Region 1 Isoform 1 (DSCR1-1L) in Endothelial Cells*
【2h】

Transcription Enhancer Factor 3 (TEF3) Mediates the Expression of Down Syndrome Candidate Region 1 Isoform 1 (DSCR1-1L) in Endothelial Cells*

机译:转录增强因子3(TEF3)介导Down的表达 内皮细胞综合征候群1亚型1(DSCR1-1L) 细胞*

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The Down syndrome candidate region 1 gene (DSCR1) can be expressed as four isoforms, one of which is the well-studied isoform 4 (DSCR1-4) that is induced by VEGF-A165 to provide a negative feedback loop in the VEGF-A165-induced angiogenesis. We reported previously that another DSCR1 isoform, DSCR1-1L, was also up-regulated by VEGF-A165 in cultured endothelial cells and in several in vivo models of pathological angiogenesis and that different from DSCR1-4, DSCR1-1L overexpression alone induced cultured endothelial cell proliferation and promoted angiogenesis in Matrigel assays. It was reported recently that tumor growth was greatly repressed in DSCR1 knock-out mice. Although DSCR1-4 transcription was primarily regulated by NFAT, the mechanism regulating DSCR1-1L expression was still unknown. We developed human DSCR1-1L promoter-driven luciferase system and found that deletion of a putative conserved M-CAT site located 1426-bp upstream of the translation start site blunted promoter activity. We further showed that knockdown of TEF3, not other members of TEF family inhibited VEGF-A165-induced DSCR1-1L expression. We also demonstrated that TEF3 directly interacted with the putative M-CAT site in the DSCR1-1L promoter in vitro and in vivo. Finally, overexpression of TEF3 isoform 1, not isoform 3, in HUVEC was sufficient to induce DSCR1-1L expression even in the absence of VEGF-A165 stimulation. Taken together, we elucidated a novel function of transcriptional factor TEF3. TEF3 was required for DSCR1-1L expression through binding to the M-CAT site in its promoter and could be an attractive target for anti-angiogenesis therapy.
机译:唐氏综合症候补区1基因(DSCR1)可以表示为四种同工型,其中之一是经过充分研究的同工型4(DSCR1-4),由VEGF-A165诱导以在VEGF-A165中提供负反馈环诱导的血管生成。我们先前曾报道过,VEGF-A165在培养的内皮细胞和几种病理性血管生成的体内模型中,还通过VEGF-A165上调了另一种DSCR1亚型DSCR1-1L,与DSCR1-4不同,DSCR1-1L的过表达单独诱导了培养的内皮细胞基质胶测定法检测细胞增殖并促进血管生成。最近有报道说,在DSCR1基因敲除小鼠中肿瘤的生长被大大抑制。尽管DSCR1-4转录主要受NFAT调控,但调控DSCR1-1L表达的机制仍然未知。我们开发了人类DSCR1-1L启动子驱动的荧光素酶系统,发现位于翻译起始位点上游1426 bp的假定保守M-CAT位点的缺失使启动子活性减弱。我们进一步表明敲除TEF3,而不是其他TEF家族成员抑制VEGF-A165诱导的DSCR1-1L表达。我们还证明了TEF3在体外和体内与DSCR1-1L启动子中的推定M-CAT位点直接相互作用。最后,即使在没有VEGF-A165刺激的情况下,HUVEC中TEF3亚型1(而非亚型3)的过表达也足以诱导DSCR1-1L表达。两者合计,我们阐明了转录因子TEF3的新功能。通过与启动子中的M-CAT位点结合,DSCR1-1L表达需要TEF3,并且它可能是抗血管生成治疗的有吸引力的靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号